CNS Pharmaceuticals, Inc. (CNSP): Nasdaq/NYSE listing notice — CNS Pharmaceuticals receives Nasdaq delisting notice over equity shortfall; will request hearing

CNS Pharmaceuticals, Inc.

Nasdaq notified CNSP on Feb 14, 2024, that it failed to meet minimum $2.5M stockholders' equity requirement after extension expired.
Company intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay suspension or delisting pending the hearing.
Panel may grant an extension not to exceed August 12, 2024, but compliance is not assured.
Previous extension was granted until Feb 13, 2024; company still non-compliant.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CNS Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

February 14, 2024, the Staff notified the Company that it had not complied with the Listing Rule and as such did not meet the terms of the extension. The Staff letter stated that unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company would be subject to delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.